Rescop Opens Offices in UK and Australia
Rescop )Regulatory System Compliance Partners) has opened new offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners) has opened new offices in the UK and Australia. This expansion follows the opening of branches in Belgium and the US last year.
“The move was required to accommodate both our current and future growth in EU and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
The company was found in 2005 by Piet Vervoort and Björn Aalbers. Its headquarters is in Den Bosch, The Netherlands, and it now has eight offices. It supplies GxP compliance software and services, and assists in the following areas: system life cycle management; commissioning, qualification and validation; change management; IT Delivery and Support; and training
Read the release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
